Braveheart Bio (NASDAQ:BRVE) Director Christopher Viehbacher Purchases 83,333 Shares of Stock

Braveheart Bio, Inc. (NASDAQ:BRVE) Director Christopher Viehbacher purchased 83,333 shares of the firm’s stock in a transaction that occurred on Friday, August 7th. The stock was acquired at an average price of $18.00 per share, with a total value of $1,499,994.00. Following the completion of the purchase, the director owned 609,519 shares in the company, valued at $10,971,342. This represents a 15.84% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Braveheart Bio Price Performance

Shares of NASDAQ BRVE opened at $30.00 on Friday. Braveheart Bio, Inc. has a 1 year low of $28.47 and a 1 year high of $32.00.

Braveheart Bio Company Profile

We are a clinical‑stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (“HCM”) and other serious cardiovascular diseases. Our lead product candidate, BHB‑1893, is a next-generation oral small‑molecule cardiac myosin inhibitor (“CMI”), that we are developing for the treatment of obstructive HCM (“oHCM”) and non‑obstructive HCM (“nHCM”). Our goal is to improve the treatment options for these patients by enhancing speed of onset, depth of gradient response, systolic safety, and reversibility, and reducing prescribing complexity.